Morgan Stanley Cel Sci Corp Call Options Transaction History
Morgan Stanley
- $1.35 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding CVM
# of Institutions
71Shares Held
6MCall Options Held
27.1KPut Options Held
150K-
Vanguard Group Inc Valley Forge, PA2.41MShares$1.45 Million0.0% of portfolio
-
Black Rock Inc. New York, NY775KShares$464,8220.0% of portfolio
-
Geode Capital Management, LLC Boston, MA613KShares$367,7160.0% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ432KShares$259,2760.0% of portfolio
-
State Street Corp Boston, MA194KShares$116,1040.0% of portfolio
About CEL SCI CORP
- Ticker CVM
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,367,500
- Market Cap $26M
- Description
- CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...